GILEAD SCIENCES 885823 (Seite 328)

[Oberkassel]

Gilead Sciences Stock Rating Reaffirmed by Guggenheim (GILD)

Gilead Sciences (NASDAQ: GILD)‘s stock had its “buy” rating restated by analysts at Guggenheim in a research report issued to clients and investors on Monday. They currently have a $87.00 price target on the stock.

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Gilead Sciences in a research note to investors on Friday. They now have a $78.00 price target on the stock. Separately, analysts at Oppenheimer reiterated an “outperform” rating on shares of Gilead Sciences in a research note to investors on Wednesday, December 5th. Finally, analysts at Barclays Capital reiterated an “overweight” rating on shares of Gilead Sciences in a research note to investors on Tuesday, December 4th. They now have a $76.00 price target on the stock.

Shares of Gilead Sciences traded up 0.26% during mid-day trading on Monday, hitting $74.11. Gilead Sciences has a one year low of $36.98 and a one year high of $76.28. The company has a market cap of $56.149 billion and a P/E ratio of 22.98.

Gilead Sciences last released its earnings data on Tuesday, October 23rd. The company reported $1.00 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.94 by $0.06. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $3.84 EPS for the current fiscal year.

Quelle: Daily Political

Oberkassler

[Cameltrophy]

bin letzte woche zu 57,58€ eingestiegen und bin gespannt ob es sich lohnt...

[Oberkassel]

Gilead Can Cure Your Portfolio With Sofobuvir

Gilead Sciences' (GILD) stock price has almost doubled in the last 52 weeks. The company is successfully rolling one after another drug into the market. It has been successful in receiving FDA approval for Quad and Truvada (for HIV prevention), and is now focusing on the Sofobuvir cocktail for Hepatitis C treatment. I believe at a P/E of 17x, GILD is a bargain for any portfolio. Sofobuvir is expected to garner peaks sales of $3.8 billion, which makes me believe that the GILD growth story is still half told.

Gilead Sciences Inc

Gilead Sciences is a bio-pharmaceutical, which is involved in the development and commercialization of human therapeutics for life threatening diseases. The product portfolio of Gilead includes Truvada, Atripla, Viread, Complera/Eviplera, and Emtriva. The company has also received FDA approval of Truvada for HIV prevention. This means that now Truvada can be used by people involved in professions, where there is a higher risk of getting exposed to HIV virus e.g. nurses. The company has also received approval for its drug Quad; a combination of Emtriva and Viread. GILD is trying to diversify its anti-viral focus by venturing into cardiovascular products. Gilead and the Cardiovascular Research Foundation (CRF) are currently involved in the Phase 3 clinical trials, aimed at assessing the utility of 'Ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).'

I believe that the approval of Quad, Truvada etc are already priced-in. Therefore, investors should look towards GILD's Hepatitis C drug for stock appreciation.

Sofosbuvir for Hepatitis C

Gilead is pushing Sofobuvir for the treatment of Hepatitis C. The drug will replace Interferon, which is a standard Hepatitis C treatment, but has unpleasant side effects. The drug was initially developed by Pharmasset, which was later acquired by Gilead Sciences (Gilead acquired Pharmasset for $11 billion). Gilead is pushing for a Hepatitis treatment by the combination of Sobuvir and Ribavirin. The company announced positive late-stage trail results for this treatment last week. In the 12 weeks after completing the therapy, 78% patients taking the drug did not have the virus. The safety profile of the drug was similar to previous studies conducted by the company. According to Chief Scientific Officer Norbert Bischofberger, Gilead plans to share the complete data on the study in first half of 2013 and submit its first regulatory filings for Sofosbuvir by mid-2013.

I believe the potential of Sofobuvir success is still not priced in. According to Credit Suisse, the market for Hepatitis C can reach $20 billion by 2015, and according to Barclays, Sofobuvir can reach sales of $3.8 billion at its peak. The only problem remains the downside risk of more entries in to the Hepatitis C market due to its huge potential of $20 billion. There are already some solid competitors in the market ,e.g. Abbott Laboratories (ABT) and Achillion Pharmaceuticals (ACHN). Despite the expected competition, the recent trial results are big news for Gilead investors, and with expected sales of $3.8 billion, Sofobuvir can drive GILD growth.

Valuations

GILD is currently trading at a forward P/E of 16.9x and P/S of 6.0x. The average P/E of NASDAQ is 19x and biopharmaceuticals industry's P/E is 24x. The PEG ratio of GILEAD is 1.03x, i.e. growth of 16%. I believe with the Hepatitis C and cardiovascular products, GILD can drive much more growth than the market is expecting; not to forget Quad and Truvada (HIV prevention). The mean target price from the sell side is $84, an upside of 14% on current valuations. The following targets can be established using average multiples and consensus estimates:

Industry P/E
NASDAQ P/E

P/E
19x
24x

Consensus EPS
$ 4.39
$ 83
$ 105

High EPS
$ 5.05
$ 96
$ 121

Low EPS
$ 3.89
$ 74
$ 93


The bold values in the table above represent target prices for GILD from each set of EPS estimates and P/E. As the table shows, under each scenario the price is greater than the current price, other than using industry P/E and lowest sell side EPS estimate. This is why I believe GILD is one of the best, if not the best pharmaceutical stock. The stock has the potential to give capital appreciation of up to 40% (using target price of $105 for December 2013). Therefore I believe GILD is a buy and a must have for any portfolio.

Quelle: Seekingalpha

Long Term Invest !

Oberkassler

[Oberkassel]

Gilead Sciences, Inc. : Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients

Gilead Sciences (Nasdaq:GILD) today announced topline results from the Phase 3 POSITRON study examining a 12-week course of once-daily sofosbuvir plus ribavirin (RBV) in patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who are not candidates to take interferon (IFN). The study found that 78 percent of patients (n=161/207) remained HCV RNA undetectable 12 weeks after completing therapy (SVR12). The safety profile of sofosbuvir was similar to that observed in previous studies, and there were few treatment discontinuations due to adverse events.

POSITRON is the first of three Phase 3 studies to be completed that are evaluating sofosbuvir therapy in HCV genotype 2 or 3 infected patient populations.

"Achieving a sustained virologic response in three quarters of patients is an impressive result for a sofosbuvir-based, all-oral treatment in a group of individuals for which no suitable alternative therapy exists. These patients by definition had previously declined interferon-based therapy, were ineligible to receive interferon, or were interferon intolerant," said Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer, Gilead Sciences. "We look forward to sharing data from additional Phase 3 studies in early 2013, and expect to submit our first regulatory filings for sofosbuvir by mid-2013."


In POSITRON, HCV genotype 2 or 3 patients who were interferon intolerant, interferon ineligible or unwilling to take interferon were randomized (3:1) to receive 12 weeks of either sofosbuvir 400 mg once daily plus weight-based RBV twice daily (n=207) or matching placebo (n=71). Of the 207 patients randomized to the sofosbuvir/RBV arm, 15 percent had compensated cirrhosis (more advanced liver disease) and 53 percent were infected with genotype 2. SVR12 rates were 93 percent in genotype 2 and 61 percent in genotype 3. In the small percentage of patients with cirrhosis at baseline who received sofosbuvir/RBV, 61 percent achieved SVR12. All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures. No patient in the placebo group achieved an SVR12. The most common adverse events reported in greater than 10 percent of patients in the study were fatigue, nausea, headache, insomnia, pruritis and anemia.

Full data from the study will be submitted for presentation at a future scientific conference.

The Phase 3 clinical trial program for sofosbuvir includes two additional studies evaluating 12 and 16 weeks of therapy with sofosbuvir plus RBV in HCV genotype 2 and 3 infected patients. A fourth Phase 3 clinical trial is evaluating sofosbuvir combined with RBV and peg-IFN among patients with HCV genotypes 1, 4, 5 and 6. Pending the results, these studies will support initial regulatory filings in mid-2013 for an all-oral therapy with sofosbuvir plus RBV among genotype 2/3 treatment-naïve, treatment-experienced and interferon-intolerant patients, and for sofosbuvir in combination with RBV and peg-IFN among treatment-naïve patients with HCV genotypes 1, 4, 5 and 6.


Quelle: 4 Traders

Heute Kurs zZ. unter 75$ gute Einstiegs- bzw. Aufstockungsoption.

Oberkassler

[Oberkassel]

Gilead Sciences PT Raised to $85.00 at Stifel Nicolaus (GILD)

Gilead Sciences (NASDAQ: GILD) had its price target boosted by Stifel Nicolaus from $80.00 to $85.00 in a research report sent to investors on Tuesday morning. The firm currently has a buy rating on the stock.

“Twelve week sofosbuvir plus BMY’s NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015.,” the firm’s analyst wrote.

Gilead Sciences traded down 1.52% on Tuesday, hitting $71.19. Gilead Sciences has a 52-week low of $34.45 and a 52-week high of $75.48. The company has a market cap of $53.937 billion and a price-to-earnings ratio of 22.47.

Several other analysts have also recently commented on the stock. Analysts at Lazard raised their price target on shares of Gilead Sciences from $89.00 to $100.00 in a research note to investors on Tuesday. They now have a buy rating on the stock. Separately, analysts at BMO Capital Markets reiterated an outperform rating on shares of Gilead Sciences in a research note to investors on Monday. They now have a $89.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a buy rating on shares of Gilead Sciences in a research note to investors on Monday. They now have a $95.00 price target on the stock, up previously from $75.00.

Quelle:ZoLMax News

Oberkassler

[Oberkassel]

Baltimore (www.aktiencheck.de) - Die Analysten von Stifel Nicolaus stufen die Aktie von Gilead Sciences (ISIN US3755581036/ WKN 885823) weiterhin mit "buy" ein. Das Kursziel werde von 80 auf 85 USD angehoben. (Analyse vom 13.11.2012) (13.11.2012/ac/a/a)

Die "Experten" geben wieder Ihre Prognosen bzw. Kursziele ab.

Oberkassler

[Oberkassel]

Gilead Sciences Inc. (GILD) had a big pop on Monday. The angle of decent shows this stock moving beautifully from the mid 40’s into the mid 70’s over the last 7 or 8 months. The key on Monday was a big breakaway gap and run up near 9 points at 8.92 to 73.93, or 14%, on 31 million shares. That’s the biggest volume since August. Although it's at the top of the channel, this stock could run to much higher levels, possibly to the mid 90’s on an intermediate basis.

Quelle:Advice Trade

Zum Schluss 73,93$ 13,72 %

Oberkassler

[Oberkassel]

Zürich (www.aktiencheck.de) - Matthew Roden, Analyst der UBS, bewertet die Aktie von Gilead Sciences (ISIN US3755581036/ WKN 885823) unverändert mit dem Rating "buy". Das Kursziel werde bei 80 USD belassen. (Analyse vom 12.11.2012) (12.11.2012/ac/a/a)

Das war deutlich mehr als ein Hüpfer !

Oberkassler

[McF]

Zitat von SLGramann: Gilead hat überragende (wenn auch vorläufige) Ergebnisse für eine GS-7977 + GS-5885-Kombi vorgestellt.
Damit hat man wieder die 100% SVR4-Rate erzielt, die man schon mal mit dem BMS-Produkt daclatasvir erreicht hatte - aber diesmal eben ohne fremde Hilfe.

Ein sehr, sehr gutes Zeichen für die gerade angelaufene PIII bei Genotype 1 Patienten.

(Etwas Wasser in den Wein: Auch Abbott mit sehr, sehr guten Ergebnissen und im Bereich der Null-Responder offenbar auch deutlich besser, als GILD.
Ich rechne für Montag trotzdem mit einem Kurshüpfer bei GILD)

10,8%,

[SLGramann]

Gilead hat überragende (wenn auch vorläufige) Ergebnisse für eine GS-7977 + GS-5885-Kombi vorgestellt.
Damit hat man wieder die 100% SVR4-Rate erzielt, die man schon mal mit dem BMS-Produkt daclatasvir erreicht hatte - aber diesmal eben ohne fremde Hilfe.

Ein sehr, sehr gutes Zeichen für die gerade angelaufene PIII bei Genotype 1 Patienten.

(Etwas Wasser in den Wein: Auch Abbott mit sehr, sehr guten Ergebnissen und im Bereich der Null-Responder offenbar auch deutlich besser, als GILD.
Ich rechne für Montag trotzdem mit einem Kurshüpfer bei GILD)


Nov 10 (Reuters) - Gilead Sciences Inc on Saturday reported a 100 percent cure rate u sing a combination of drugs i n a small number of patients with the most common and hardest to treat form of hepatitis C.

Rival Abbott Laboratories Inc, meanwhile, said a trio of its oral medicines to treat hepatitis C produced unprecedented cure rates in a larger number of patients who had failed to benefit from standard treatment, as well as very high cure rates for newly treated patients.

Data from both companies' mid-stage trials were released Saturday at the annual meeting of the American Association for the Study of Liver Disease in Boston. Gilead's study, dubbed Electron, examined 25 patients with genotype 1 chronic hepatitis C virus (HCV) infection who were treated for 12 weeks with a combination of three drugs: sofosbuvir, ribavirin and GS-5885.

GS-5885 is from a promising new class of drugs known as NS5A inhibitors, which prevent the hepatitis C virus from replicating.

The infection was undetectable four weeks after completing therapy in all of the patients who had never received this combination of drugs before, Gilead said.

The drugs generally were well tolerated in the study, Gilead said.

In the sofosbuvir combined with GS-5885 and ribavirin patient groups, one patient dropped out because of an adverse side effect that the company said was unrelated to the drugs.

Sofosbuvir and GS-5885 are still being studied for their safety and efficacy.

The biopharmaceutical company will present the data on Tuesday at the annual meeting of the American Association for the Study of Liver Diseases in Boston.

Mark Schoenebaum, a biotech analyst with ISI Group, said in a research note that he expects Gilead shares to rise on Monday based on these "best case" results.

UBS analyst Matthew Roden said "these data strongly support Gilead's leadership position" in the hepatitis C virus space.

Gilead recently started the first Phase 3 trial evaluating a fixed-dose combination of sofosbuvir and GS-5885 in patients with genotype 1 chronic hepatitis C virus infection who had not received these drugs before.

This study is evaluating the fixed-dose combination with and without ribavirin for 12- and 24-weeks in 800 patients, 20 percent of whom have evidence of cirrhosis, or liver scarring. (Reporting By Debra Sherman; Editing by Vicki Allen)